6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Monlunabant Phase 2a Trial in Obesity Successfully Completed
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons
6-K: Financial Report for the Period 1 January 2024 to 30 June 2024
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: Novo Nordisk A/S - Share Repurchase Programme
6-K: European Regulatory Authority Adopts a Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events
6-K: Novo Nordisk A/S - Share Repurchase Programme
No Data
No Data